Followers | 832 |
Posts | 119973 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Friday, February 10, 2023 4:40:56 AM
https://www.koreabiomed.com/news/articleView.html?idxno=20428
The Seoul Central District Court on Friday ruled in favor of Medytox in the lawsuit filed by Medytox against Daewoong Pharmaceutical...including the prohibition of infringement of trade secrets, and ordered Daewoong to… turn over Daewoong's BTX strain to Medytox, and discard all finished BTX products made with the strain.
The ruling comes after Medytox filed a lawsuit against Daewoong Pharmaceutical for damages of 1.1 billion won in October 2017, claiming that a former employee stole Medytox's BTX strains and product manufacturing process technical documents and provided them to Daewoong Pharmaceutical.
… After the ruling came out, Medytox immediately sent out a press release stating that it had regained the legitimate rights of its BTX strain five years and four months after filing a lawsuit against Daewoong.
… Daewoong said it will appeal the court's decision, saying that the ruling was a “clear misjudgment.”
… On Friday, Medytox's shares surged by a daily limit of 30 percent... Daewoong shares dropped…9.35 percent from the previous day.
As a side effect of the ruling, Hugel, which is currently embroiled in a U.S. International Trade Commission dispute over the origin of its strain with Medytox, also saw the stock price decline…18.17 percent from the previous day.
The ruling will also affect Evlous, which markets Daewoong's BTX products in the U.S., as all of Daewoong's BTX products are currently manufactured in Korea.
As the ruling ordered Daewoong to discard all products made with Medytox's strain, Daewoong's thriving BTX export business will likely ground to a complete halt if Daewoong fails to receive a suspension of execution from the court.
Above all, if the ruling leads to the cancellation of the license for Daewoong's BTX product, the Ministry of Food and Drug Safety may revoke its export permission.
As Evolus' revenue entirely consists of Jeuveau, the company will no longer be able to maintain sales if such a ruling happens.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent EOLS News
- Evolus Announces Appointment of Albert G. White III to Board of Directors • Business Wire • 07/01/2024 12:00:00 PM
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products • Business Wire • 06/24/2024 12:00:00 PM
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain • Business Wire • 06/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:21 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/07/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:01:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:45:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 01:30:56 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 09:22:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:25:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 09:53:10 PM
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting • Business Wire • 05/20/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 09:19:49 PM
- Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit • Business Wire • 05/15/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 12:56:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 12:55:50 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 12:06:13 AM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/10/2024 10:55:00 PM
- Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year • Business Wire • 05/10/2024 01:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 09:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:14:16 PM
- Evolus Reports First Quarter 2024 Results and Provides Business Update • Business Wire • 05/07/2024 08:05:00 PM
- Evolus to Report First Quarter Financial Results on May 7, 2024 • Business Wire • 04/23/2024 08:30:00 PM
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® • Business Wire • 04/17/2024 08:05:00 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/12/2024 08:05:00 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM